TNBC remains the most challenging breast cancer subtype to treat not only for the lack of ER, PgR and HER2 as therapeutic targets but also for the high heterogeneity that makes the management of this disease even more difficult [30]. This evidence concerns the gene ERBB2 and breast carcinoma.